Cargando…
Lifestyle or pharmacotherapy in cardio-metabolic disease prevention
Cardio-metabolic diseases are the leading causes of premature death worldwide. The conditions are together some of the most prevalent and severe multimorbidities and include conditions such as diabetes, hypertension, coronary heart disease and stroke. People with these conditions are at a higher ris...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334018/ https://www.ncbi.nlm.nih.gov/pubmed/37381922 http://dx.doi.org/10.1177/17539447231177175 |
_version_ | 1785070784339771392 |
---|---|
author | Seidu, Borenyi S. Osman, Hanad Seidu, Samuel |
author_facet | Seidu, Borenyi S. Osman, Hanad Seidu, Samuel |
author_sort | Seidu, Borenyi S. |
collection | PubMed |
description | Cardio-metabolic diseases are the leading causes of premature death worldwide. The conditions are together some of the most prevalent and severe multimorbidities and include conditions such as diabetes, hypertension, coronary heart disease and stroke. People with these conditions are at a higher risk of all-cause death and have a reduction in life expectancy when compared to patients without cardio-metabolic disorders. As a result of the increasing prevalence and impact of cardio-metabolic multimorbidity on disability, no healthcare system can ‘treat’ its way out of this pandemic. ‘Treating our way out’ requires the use of multiple medications which can lead to improper prescribing, insufficient compliance, overdosing or underdosing, improper drug choice, insufficient monitoring, unfavourable drug effects, and drug interactions and inappropriate wastes and costs. Therefore, individuals living with these conditions should be empowered to adopt lifestyle changes that foster independent living with their conditions. Adopting these healthy lifestyles such as smoking cessation, improving dietary habits, sleep hygiene and physical activity is a suitable adjunctive measure if not an alternative to polypharmacy in cardio-metabolic multimorbidity. |
format | Online Article Text |
id | pubmed-10334018 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-103340182023-07-12 Lifestyle or pharmacotherapy in cardio-metabolic disease prevention Seidu, Borenyi S. Osman, Hanad Seidu, Samuel Ther Adv Cardiovasc Dis Review Cardio-metabolic diseases are the leading causes of premature death worldwide. The conditions are together some of the most prevalent and severe multimorbidities and include conditions such as diabetes, hypertension, coronary heart disease and stroke. People with these conditions are at a higher risk of all-cause death and have a reduction in life expectancy when compared to patients without cardio-metabolic disorders. As a result of the increasing prevalence and impact of cardio-metabolic multimorbidity on disability, no healthcare system can ‘treat’ its way out of this pandemic. ‘Treating our way out’ requires the use of multiple medications which can lead to improper prescribing, insufficient compliance, overdosing or underdosing, improper drug choice, insufficient monitoring, unfavourable drug effects, and drug interactions and inappropriate wastes and costs. Therefore, individuals living with these conditions should be empowered to adopt lifestyle changes that foster independent living with their conditions. Adopting these healthy lifestyles such as smoking cessation, improving dietary habits, sleep hygiene and physical activity is a suitable adjunctive measure if not an alternative to polypharmacy in cardio-metabolic multimorbidity. SAGE Publications 2023-06-29 /pmc/articles/PMC10334018/ /pubmed/37381922 http://dx.doi.org/10.1177/17539447231177175 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Seidu, Borenyi S. Osman, Hanad Seidu, Samuel Lifestyle or pharmacotherapy in cardio-metabolic disease prevention |
title | Lifestyle or pharmacotherapy in cardio-metabolic disease
prevention |
title_full | Lifestyle or pharmacotherapy in cardio-metabolic disease
prevention |
title_fullStr | Lifestyle or pharmacotherapy in cardio-metabolic disease
prevention |
title_full_unstemmed | Lifestyle or pharmacotherapy in cardio-metabolic disease
prevention |
title_short | Lifestyle or pharmacotherapy in cardio-metabolic disease
prevention |
title_sort | lifestyle or pharmacotherapy in cardio-metabolic disease
prevention |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334018/ https://www.ncbi.nlm.nih.gov/pubmed/37381922 http://dx.doi.org/10.1177/17539447231177175 |
work_keys_str_mv | AT seiduborenyis lifestyleorpharmacotherapyincardiometabolicdiseaseprevention AT osmanhanad lifestyleorpharmacotherapyincardiometabolicdiseaseprevention AT seidusamuel lifestyleorpharmacotherapyincardiometabolicdiseaseprevention |